Please find enclosed herewith Outcome of Board Meeting .
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported FY2026 audited results with standalone revenue of Rs. 6,651 crore (up 10% YoY) and consolidated revenue of Rs. 7,345 crore (up 10% YoY). Standalone PAT grew 27.3% to Rs. 640 crore while consolidated PAT rose 15.7% to Rs. 675 crore. EBITDA margins expanded to 16.82% (standalone) and 16.03% (consolidated) from 15.74% and 15.78% respectively. Exceptional items include Rs. 48.64 crore labour code impact, Rs. 18.35 crore Sikkim asset write-down, partially offset by Rs. 12.87 crore insurance recovery and Rs. 100.27 crore deferred tax asset recognition. Board recommended dividend of Rs. 12 per share (600%) vs Rs. 11 (550%) prior year. Auditors issued unmodified opinion.
Strong bottom-line growth driven by margin expansion and one-time tax benefits. The Sikkim facility write-down is a concern but largely offset by insurance recovery. Dividend increase signals confidence in financial health.